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Abstract 
Evidence from epidemiologic studies that central obesity precedes future metabolic change 
and does not occur concurrently with the appearance of the blood pressure, glucose and lipid 
abnormalities that characterize the metabolic syndrome (MetS) has been lacking. 
Longitudinal surveys were conducted in Mauritius in 1987, 1992 and 1998, and in Australia 
in 2000 and 2005 (AusDiab). This analysis included men and women (aged ≥25 years) in 
three cohorts: AusDiab 2000 to 2005 (n=5039), Mauritius 1987 to 1992 (n=2849) and 
Mauritius 1987 to 1998 (n=1999). MetS components included waist circumference, systolic 
blood pressure, fasting and 2-hour post load plasma glucose, HDL cholesterol, triglycerides 
and HOMA-S (representing insulin sensitivity). Linear regression was used to determine 
which baseline components predicted deterioration in other MetS components over five years 
in AusDiab and five and eleven years in Mauritius, adjusted for age, sex and ethnic group. 
Baseline waist circumference predicted deterioration (p<0.01)  in four out of the other six 
MetS variables tested in AusDiab, five out of six in Mauritius 87-92, and four out of six in 
Mauritius 87-98. In contrast, an increase in waist circumference between baseline and follow-
up was only predicted by insulin sensitivity (HOMA-S) at baseline, and only in one out of the 
three cohorts.  
These results suggest that central obesity plays a central role in the development of the MetS 
and appears to precede the appearance of the other MetS components. 
Keywords 
Central obesity, Metabolic Syndrome, Epidemiology 
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Introduction 
Substantial evidence exists for the important role of obesity in the development of the 
metabolic syndrome (MetS), with obesity being included as a required pre-requisite in the 
most recent International Diabetes Federation MetS definition. Indeed, both cross-sectional 
and longitudinal factor analyses have implicated obesity as a central feature of this multi-
faceted condition.(1, 2) However, whether obesity precedes future metabolic change or 
occurs concurrently with the deterioration in blood pressure, glucose levels and lipid 
abnormalities that characterize the MetS is an important question that has remained unclear. 
The implications of this question for the metabolic syndrome relate to whether the 
importance of obesity is merely as one of several components in clinical definitions, or 
whether it is actually most important before the development of other metabolic syndrome 
abnormalities and when the best opportunity for prevention exists. 
The few studies that have used longitudinal data to examine the temporal relationships 
between the components of the MetS have all implicated baseline obesity, the increase in 
obesity between baseline and follow-up or insulin resistance as being the strongest predictors 
of deterioration in MetS components or the progression to diabetes.(2-8) None of these 
studies, however, have examined whether the pre-existing central obesity that so often 
accumulates over the life course, precedes deterioration in the other MetS components.  
The theoretical model on which this research is based is that if several of the measured MetS 
components are similarly related to an unmeasured underlying cause, it would be expected 
that they would develop concurrently, and that in some people one of these components 
would appear first, while in others another component would be the first abnormality to 
develop. If, however, one of the MetS components (e.g. central obesity) was itself the 
underlying cause, it would be expected that this component should predict deterioration in the 
other components, but not vice versa. By examining the relationships between all MetS 
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components at baseline and change in all other MetS components between baseline and 
follow-up, an assessment of the validity of these two scenarios is possible. 
In this analysis, we use data from two large, national, longitudinal studies (the Australian 
Diabetes, Obesity and Lifestyle study (AusDiab) and the Mauritius Non-Communicable 
Diseases Study) to explicitly assess using the theoretical model described, whether central 
obesity precedes subsequent deterioration in each of the other elements of the MetS. 
Methods and Procedures 
Survey procedures 
The study methods and response for both the AusDiab and Mauritius surveys have been 
described in detail elsewhere.(9-12) In brief, the AusDiab study was a population-based 
survey of 11 247 adults (5049 men and 6198 women), aged ≥25 years in 1999 to 2000 
(response was 55.3% of those completing a household interview). A stratified cluster sample 
was drawn from 42 randomly selected Census Collector Districts across Australia (six in each 
of the States and the Northern Territory). Five years later in 2004 & 2005, 6400 (57%) 
participants were re-surveyed. A comparison of the profile of responders vs. non-responders 
to the AusDiab survey has been published previously.(13)  
In Mauritius, all persons over 24 years of age living in selected areas were invited to attend a 
survey in 1987. The response was 80% (n=5083). Of these, 74.2% (n=3771) were followed 
up in 1992 and 55.1% (n=2802) were followed up in 1998.  
For both the AusDiab and Mauritius surveys, a 75g oral glucose tolerance test (OGTT) was 
performed on all non-pregnant participants, except those taking insulin or oral hypoglycaemic 
drugs, at all surveys. Biochemical measurements, height, weight, hip and waist circumference 
and blood pressure for all surveys were measured as previously described.(13-15) Elements 
of the MetS used in this analysis included the five proposed in each of the IDF and NCEP-
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ATPIII definitions (waist circumference, triglyceride and HDL cholesterol concentration, 
glucose and blood pressure) as well as insulin sensitivity due to its close links to the MetS 
and the possibility that it is an underlying cause. Systolic blood pressure was chosen to 
represent hypertension (results were similar when diastolic blood pressure was used – data 
not shown), and both fasting and two hour post load plasma glucose were included to 
represent the glucose component. Diabetes was classified according to the World Health 
Organization (WHO) criteria and those with diabetes at baseline or who developed diabetes 
between baseline and follow-up, as well as those on anti-hypertensive agents were excluded 
from all analyses.(16) Women who were pregnant at any survey were excluded. In AusDiab 
only (because this information was not available for Mauritius), participants reporting non-
skin cancers during any of the annual follow-up surveys were excluded from all analyses. 
After exclusions, the numbers available for analysis were Mauritius 1987 to 1992, n=2849; 
Mauritius 1987 to 1998, n=1999 (note that 1807 individuals were common to both cohorts); 
and AusDiab 2000 to 2005, n=5039.  
The AusDiab survey protocols were approved by the ethics committee of the International 
Diabetes Institute and Monash University’s Standing Committee on Ethics in Research 
involving Humans (SCERH). The Mauritius survey protocols were reviewed and approved 
by the Alfred Healthcare Group Ethics Committee (Melbourne, Australia) as well as the 
Ministry of Health, Mauritius. Informed consent was obtained from all participants of both 
surveys. 
Statistical Analysis 
Statistical analysis was conducted using Stata 9.0 (College Station, Texas, USA). Means 
(±SD) or proportions of various physical and demographic characteristics were calculated for 
those attending baseline and follow-up studies. The technique used to assess temporal order 
was a cross-lagged panel design (CLPD), where the theoretical model is that the probable 
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cause (obesity) of a cluster of conditions is not itself caused by these conditions. Therefore 
the probable cause will predict the development of the conditions, but the conditions will not 
predict the development of the probable cause. Separate univariate linear regression models 
were used to assess the association between individual baseline MetS variables and the 
change in each of the other MetS variables respectively between baseline and follow-up (each 
model also included the dependent variable measured at baseline), with standardized 
regression coefficients reported. Further multivariate analysis included all six MetS 
components as co-variates in these models. The mean variance inflation factor (VIF) for these 
multivariable models was calculated (in AusDiab, mean VIF =1.46, in Mauritius, mean 
VIF=1.34), indicating an absence of co-linearity in the models. Analysis of change in 
parameters between baseline and follow-up was based on the model suggested by Vickers 
and Altman.(17) It should be noted that for all regression analyses, the glucose, waist 
circumference, lipid, HOMA-S and systolic blood pressure variables were entered as 
continuous variables, not as dichotomous variables as are used in clinical definitions of the 
MetS. To account for the possibility that significant results may simple be due to multiple 
comparisons, p<0.01 was considered significant. All analyses were adjusted for age, sex and 
(in Mauritius) ethnic group. It is acknowledged that some of the relationships between 
different metabolic syndrome variables presented are unlikely, for instance, blood pressure 
predicting change in HDL cholesterol and triglycerides. These relationships are included to 
emphasize the difference between these relationships and those involving more plausible 
predictors such as obesity and insulin sensitivity, and for completeness. If the relationships 
seen for plausible predictors and change in the other metabolic syndrome variables were due 
to chance, or because of the nature of the variables themselves, similar relationships would 
also be expected for implausible associations.  
7 
 
Results 
The baseline characteristics for those who attended both the baseline and follow-up AusDiab 
(2000 & 2005) and Mauritius (1987 & 1992; 1987 & 1992 & 1998) surveys are presented in 
Table 1.  At baseline, subjects in Australia compared to Mauritius were on average older, 
having higher BMI, waist circumference and HOMA-S and having lower diastolic blood 
pressure and two hour post load plasma glucose.  
[Insert Table 1 here] 
Impact of individual baseline MetS components on change in other MetS components 
over five and 11 years 
The univariate associations between each of the individual MetS components at baseline with 
change in other MetS components between baseline and follow-up in Mauritius (1987 to 
1992 and 1987 to 1998) and AusDiab (2000 to 2005), adjusted for age, sex and ethnic group 
(in Mauritius only), but not other MetS components, are shown in Table 2. To account for the 
possibility that significant results may simple be due to multiple comparisons, p<0.01 was 
considered significant. Baseline waist circumference was associated with change in each of 
the other six MetS components tested in each of the three cohorts (all p<0.01 and in the 
expected direction, with the exception of triglycerides where p=0.015 for the Mauritius 87-98 
cohort). In Mauritius, only baseline two hour post load plasma glucose (p=0.002) in the 
eleven year cohort was significantly associated with change in waist circumference, however 
the association was with a decrease rather than an increase in waist circumference. In 
AusDiab, baseline HDL cholesterol (p=0.001) was associated with an increase in waist 
circumference, while HOMA-S (p<0.0001) was associated with a decrease in waist 
circumference. Baseline triglycerides was also associated with an increase in waist 
circumference (p=0.016), however this did not quite reach significance at p<0.01.  
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[Insert Table 2 here] 
Further multivariate regression models including all six baseline MetS components as 
covariates (plus age and sex (and ethnic group in Mauritius)) are presented in Table 3. A 
similar pattern to the univariate analysis is seen. Waist circumference at baseline was strongly 
associated with deterioration in each of the other six MetS components in each of the three 
survey periods, with the only exceptions being change in HDL cholesterol and triglycerides 
in Mauritius 1987-1998 (p=0.055 and 0.085 respectively), change in HDL cholesterol and 
triglycerides in AusDiab (p=0.170 and p=0.021 respectively), and change in systolic blood 
pressure in Mauritius 1987-1992 (p=0.142). Only baseline 2-hour post load glucose in the 
1987-1998 Mauritius cohort (p=0.001) and HOMA-S (p<0.0001) in AusDiab were associated 
with change in waist circumference, however for 2-hour post load glucose in Mauritius, this 
association was with a decrease in waist circumference.  
[Insert Table 3 here] 
Figure 1 represents a summary of all significant relationships from Table 3, with the central 
component representing an individual baseline predictor, and the six satellite components 
surrounding each representing the six follow-up variables. Where arrows are present, this 
represents significant associations (p<0.01) between the baseline variable and change in the 
satellite component for each of the AusDiab and five and eleven year Mauritius follow-up 
studies. Baseline waist circumference was significantly associated with deterioration in four 
out of six other MetS variables in AusDiab, with deterioration in five out of six MetS 
variables in Mauritius 87-92, and with deterioration in four out of six MetS variables in 
Mauritius 87-98. In contrast, an increase in waist circumference between baseline and follow-
up was only predicted by insulin sensitivity (HOMA-S) at baseline, and only in one out of the 
three cohorts. While baseline triglyceride levels predicted deterioration in other MetS 
variables on 10 occasions (compared to 13 for waist circumference), a rise in triglyceride 
9 
 
levels was also predicted by other baseline parameters on five occasions. Similar, although 
slightly attenuated findings were also found when the Mauritius cohort was divided into 
ethnic Asian Indian and Creole cohorts. 
 [Insert Figure 1 here] 
The association between waist circumference at baseline and the development of the 
metabolic syndrome as a whole (defined according to the NCEP-ATPIII definition) was also 
assessed. As a continuous variable, adjusted for the same variables as included in tables 2 and 
3, waist circumference was the strongest predictor of incident metabolic syndrome (p<0.0001 
in AusDiab and both Mauritius cohorts). Similarly adjusted, obesity as a dichotomous 
variable (as defined in the NCEP-ATPIII MetS definition) was strongly associated with 
incident MetS in AusDiab (OR 3.9 (95%CI 3.0-5.0)) and Mauritius (1987 to 1992 (OR 2.9 
(2.3-3.6)) and 1987 to 1998 (OR 3.1(2.4-4.1))). 
Discussion 
Over five years in the AusDiab study and in cohorts spanning both five and eleven years in 
Mauritius, we have shown here a strong association between waist circumference and 
deterioration in other MetS parameters in both univariate and multivariate analyses. In 
contrast, the corresponding relationship between those other MetS parameters and increasing 
waist circumference is not seen. These results are suggestive of a temporal relationship 
whereby central obesity is the first component of the MetS to develop, preceding 
deterioration in each of the other components. 
 Whether waist circumference is in the middle of a causal pathway leading from insulin 
insensitivity, to obesity and then the development of the MetS is an interesting hypothesis 
that is not ruled out from the results presented in Table 3. If this were the case, however, 
repeating the analysis without including waist circumference would be expected to reveal a 
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strong relationship between insulin sensitivity at baseline and the variables of the MetS and 
not vice versa. This is not seen however (data not shown), suggesting that the absence of a 
strong temporal relationship between insulin sensitivity and variables of the MetS is not due 
to the presence of waist circumference in the model. In addition, whether insulin sensitivity 
precedes hypertension has been a controversial question and our results are inconclusive on 
this topic.(18) 
Support for the role of central obesity in the pathogenesis of the MetS has come from both 
epidemiology and physiology. The physiologic link between adipose tissue and metabolic 
deterioration is based on evidence including the  role played by factors such as free fatty 
acids and tumour necrosis factor-alpha (TNF-α) in impairing insulin action in skeletal 
muscle.(19, 20) Obesity-induced inflammation is also being increasingly implicated in insulin 
resistance,(21) with the adipokine adiponectin shown to have anti-diabetic, anti-
atherosclerotic and anti-inflammatory functions,(22) and high levels of this hormone being 
negatively associated with obesity, insulin resistance and type 2 diabetes.(23)  
Elevated concentrations of leptin, another adipokine, have consistently been independently 
associated with an increased diabetes, cardiovascular disease risk and the metabolic 
syndrome (12, 24-26); and visfatin, as well as peptides such as plasminogen activator 
inhibitor-1 (PAI-1) have also been shown to play key roles in the process of metabolic 
deterioration.(27, 28)  
More directly, assessment of intra-abdominal fat mass through computed tomography has 
been shown to be strongly and independently associated with each of the five components of 
the ATPIII definition of the MetS.(29) The complexity of the physiologic pathways 
connecting central obesity and other MetS risk factors mean that the precise process by which 
central obesity and/or visceral fat interacts with insulin resistance and the MetS is far from 
clear at present. Our results do not rule out the possibility that an unmeasured variable affects 
11 
 
each of the components of the MetS individually, but that obesity simply develops earlier, 
however the physiologic evidence outlined above directly linking obesity and each of the 
MetS components suggests that this is unlikely to be the case. 
Epidemiologic evidence directly supporting the positioning of obesity at the start of the MetS 
pathway is not substantial. Several longitudinal studies have examined the role of obesity in 
the development of the MetS but none have explicitly addressed the question of whether 
obesity precedes the development of the other components. A 4.5 year longitudinal factor 
analysis placed BMI at the centre of the three MetS factors identified.(2) Three other studies 
have all concurred that obesity appears to be the central feature of the MetS, with a French 
study assessing change in weight and parallel change in other MetS parameters; the IRAS 
study being used to determine predictors of incident MetS as a whole; and the observation 
from the ARIC study that obesity was the best predictor of the development of one or more 
MetS components.  None of these studies, however, have provided compelling data on the 
temporality of this association.(3, 4, 6) Evidence for the association between obesity and 
deterioration in individual MetS components has been presented for hypertension and 
hyperinsulinaemia,(7, 30) although in Pima Indians, an inverse relationship between obesity 
and hyperinsulinaemia was observed, perhaps reflecting an early expression of a thrifty 
genotype prior to obesity in this population.(31)  
The most recent MetS definition proposed by the International Diabetes Federation (IDF) 
acknowledged the importance of central obesity in the MetS by making this a required 
component for clinical diagnosis.(32) Our results suggest that although central obesity is 
clearly important as a component of clinical MetS definitions, it should be emphasized that it 
appears to precede development of the other component abnormalities and when present in 
isolation is therefore likely to be an important warning sign for future metabolic syndrome. 
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To prevent the rising global tide of diabetes and the MetS, our results would suggest that 
priority be given to reducing rates of overweight and obesity. 
The similar result observed in two contrasting national, population-based samples including 
multiple ethnic groups (Asian Indians, Creoles and Europids in particular), in a developed 
and a developing nation and with different prevalence of the MetS, incidence of diabetes and 
follow-up period (13, 15, 33) strengthens the validity of the findings and the generalisability 
of them to the pathogenic process that is the MetS. To our knowledge this is the first attempt 
to explicitly investigate a temporal relationship between all of the components of the MetS. 
Cross-lagged panel (or unbalanced reciprocity) designs have been shown to have limitations 
in determining temporal order if measurements are unreliable and if the possibility that 
concurrent change is responsible for an observed association is not accounted for.(34) The 
objective nature of the variables of interest, the significant amount of time between surveys in 
the Mauritius and AusDiab studies and the strength of the observed associations all reduce 
the likelihood that these issues are of concern in this analysis. Future research utilizing 
multiple time points and using discrete-time survival modeling approaches may assist in 
further exploring the precise temporal relationships that have been suggested here, and in 
more precisely quantifying the magnitude of the relationships observed. 
In AusDiab, fasting insulin measurement at baseline utilized a human insulin-specific 
radioimmuoassay kit, while at follow-up, insulin was measured using a Chemiluminescence 
method, with the two methods having been shown to result in different mean values in a 
comparison of insulin assay types.(35) For this reason, the differences in the values of 
HOMA-S between baseline and follow-up in AusDiab (Table 1) are not easily interpreted. 
The important aspects of the statistical analyses presented here, however, are the relative 
changes between individuals, not the actual difference between measurements at baseline and 
follow-up. Consequently the strength of association observed should not be affected by 
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differences in measurement techniques. The exclusion of those on blood pressure lowering 
medication and with diabetes could be criticized due to the likelihood that these individuals 
are the most likely to have undergone significant decline in MetS parameters. In analyses 
where those on medication for hypertension and those with diabetes at baseline were included 
(results not shown), similar patterns were observed that if anything were stronger in their 
support of waist circumference as the precursor to metabolic deterioration.  
If the null hypothesis was true (that all parameters were equally related to outcomes) but the 
reason for our findings was simply that waist circumference was more accurately measured 
than the other parameters, we should also expect that deterioration in waist circumference 
would be predicted by several baseline parameters. Since this was not seen, however, this 
does not seem to be a plausible explanation of the findings.  
This work adds support to the hypothesis that central obesity is at the core of the metabolic 
syndrome, and is the antecedent to deterioration in its other components. From a clinical and 
public health perspective, the clear implication is that preventing or reducing obesity must be 
the primary focus of efforts to prevent the now well documented global epidemic of diabetes 
and its related complications. This work clearly suggests that elevation in waist 
circumference occurs before deterioration in the other components of the MetS has occurred, 
and that central obesity is therefore the flag bearer for the MetS. Compelling evidence from 
lifestyle intervention trials (36-39) suggests that it is indeed possible to reduce the risk of 
developing diabetes and features of the MetS, and we have added further evidence to suggest 
that reduction in adiposity, and in particular central obesity, should be the goal for those 
wishing to reduce their risk of the MetS and its associated outcomes.  
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Figure 1. Significant associations1 between MetS components at baseline (centre) and change 
in other components between baseline and follow-up (satellites). Graphical representation of 
data from Table 3. 
Table 1. Baseline and follow-up characteristics of participants in 2000 and 2005 (AusDiab); 
1987 and 1992 (Mauritius) and 1987 and 1998 (Mauritius). 
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Figure 1 Footnotes. 
1Each linear regression model includes all six baseline MetS components plus age, sex, the 
dependent variable at baseline (not shown – included in order to model change) and (in 
Mauritius) ethnic group as covariates – data taken from Table 3. Each arrow represents one of 
the three cohorts tested (5 year AusDiab, 5 and 11 year Mauritius). 
20 
 
2 Arrows represent those associations where the baseline variable (in the central circle) was 
associated with a deterioration in the outcome variable (in the satellites). A p-value of <0.01 
was considered significant due to the multiple comparisons being made. 
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Table 1. Baseline and follow-up characteristics of participants in 2000 and 2005 (AusDiab); 1987 and 1992 
(Mauritius) and 1987 and 1998 (Mauritius). 
  AusDiab Mauritius 
  2000-2005 1987-1992 1987-1998 
  2000 2005 1987 1992 1987 1998 
n 5039 2849 1999 
Male 44.9 (43.6-46.3) 
 
47.1 (45.2-48.9)   45.2 (43.0-47.4)   
Age (years) 49.0 (48.6-49.3) 54.0 (53.6-54.3) 40.3 (39.9-40.8) 45.3 (44.9-45.7) 38.9 (38.4-39.4) 50.4 (49.9-50.9) 
Weight (kg) 75.4 (75.0-75.9) 77.1 (76.7-77.6) 57.7 (57.2-58.1) 60.5 (60.0-60.9) 57.5 (57.0-58.0) 63.5 (62.9-64.0) 
Waist Circumference (cm) 88.7 (88.4-89.1) 90.9 (90.5-91.3) 74.8 (74.4-75.1) 83.2 (82.9-83.6) 74.3 (73.9-74.7) 82.7 (82.2-83.1) 
BMI (kg/m2) 26.3 (26.2-26.4) 27.2 (27.0-27.3) 23.2 (23.1-23.4) 24.6 (24.4-24.7) 23.1 (23.0-23.3) 25.1 (24.9-25.3) 
Waist:Hip ratio 0.85  (0.85-0.86) 0.87  (0.86-0.87) 0.84  (0.83-0.84) 0.87  (0.87-0.87) 0.83  (0.83-0.84) 0.85  (0.84-0.85) 
Systolic Blood Pressure (mmHg) 125.2 (124.8-125.6) 120.9 (120.4-121.4) 121.9 (121.4-122.5) 120.3 (119.7-121.0) 120.2 (119.5-120.8) 126.0 (125.1-126.8) 
Fasting plasma glucose (mmol/L) 5.3  (5.3-5.3) 5.3  (5.3-5.3) 5.2  (5.2-5.2) 5.6  (5.6-5.7) 5.1  (5.1-5.2) 5.8  (5.7-5.9) 
2hr Plasma glucose (mmol/L) 5.8  (5.7-5.8) 5.7  (5.6-5.7) 6.2  (6.2-6.3) 6.9  (6.8-7.0) 6.2  (6.1-6.2) 7.6  (7.4-7.7) 
HOMA-S (units)1 64.6 (63.8-65.5) 111.7 (109.9-113.6) 39.1 (38.5-39.7) 43.3 (42.1-44.5) 39.6 (38.9-40.3) 45.4 (44.1-46.6) 
Serum Triglycerides (mmol/L)1 1.2  (1.2-1.2) 1.2  (1.2-1.2) 1.2  (1.1-1.2) 1.2  (1.2-1.2) 1.1  (1.1-1.2) 1.3  (1.3-1.3) 
Serum HDL cholesterol (mmol/L) 1.5  (1.4-1.5) 1.5  (1.4-1.5) 1.3  (1.3-1.3) 1.3  (1.3-1.3) 1.3  (1.3-1.3) 1.0  (1.0-1.0) 
Data are percentages, means or 1geometric mean (95% confidence interval) 
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Table 2. Univariate relationships between MetS components at baseline and change in each other component between baseline 
and follow-up.  
  
Mauritius 1987-1992   Mauritius 1987-1998   AusDiab 2000-2005 
Baseline predictor 
variable1 Outcome variable at followup2 Coef. 
Std 
Beta P   Coef. 
Std 
Beta P   Coef. 
Std 
Beta P 
HDL Cholesterol 
(mmol/L) 
2-hour Post Load Plasma Glucose -0.09 -0.03 0.076   -0.23 -0.05 0.042   -0.13 -0.09 <0.0001 
Fasting Plasma Glucose -0.34 -0.05 0.006   -0.70 -0.06 0.007   -0.34 -0.08 <0.0001 
Waist Circumference -0.26 -0.01 0.402   0.33 0.01 0.453   -0.96 -0.03 0.001 
Ln(Triglycerides) -0.14 -0.09 <0.0001   -0.10 -0.07 <0.0001   -0.27 -0.12 <0.0001 
Systolic Blood Pressure -1.25 -0.02 0.084   -2.54 -0.04 0.017   -2.03 -0.04 <0.0001 
HOMA-S 16.93 0.09 <0.0001   14.55 0.11 <0.0001   51.18 0.27 <0.0001 
Fasting Plasma 
Glucose (mmol/L) 
HDL Cholesterol -0.01 -0.02 0.207   0.00 0.00 0.920   -0.01 -0.01 0.118 
2-hour Post Load Plasma Glucose 0.65 0.14 <0.0001   0.97 0.13 <0.0001   0.42 0.12 <0.0001 
Waist Circumference -0.13 -0.01 0.513   -0.22 -0.01 0.448   -0.46 -0.02 0.033 
Ln(Triglycerides) 0.07 0.08 <0.0001   0.03 0.04 0.059   0.07 0.04 0.001 
Systolic Blood Pressure 1.03 0.03 0.031   0.96 0.03 0.177   1.67 0.04 <0.0001 
HOMA-S 4.54 0.04 0.049   6.13 0.07 0.001   -22.44 -0.14 <0.0001 
2-hour Post Load 
Plasma Glucose 
(mmol/L) 
HDL Cholesterol -0.01 -0.03 0.082   -0.01 -0.03 0.132   -0.01 -0.02 0.026 
Fasting Plasma Glucose 0.10 0.15 <0.0001   0.21 0.19 <0.0001   0.04 0.09 <0.0001 
Waist Circumference -0.15 -0.02 0.031   -0.29 -0.04 0.002   0.06 0.01 0.356 
Ln(Triglycerides) 0.02 0.05 0.001   0.01 0.04 0.046   0.01 0.01 0.275 
Systolic Blood Pressure 0.24 0.02 0.140   0.46 0.04 0.050   0.45 0.04 0.001 
HOMA-S -1.18 -0.03 0.128   0.12 0.00 0.843   -6.38 -0.13 <0.0001 
Waist Circumference 
(cm) 
HDL Cholesterol 0.00 -0.13 <0.0001   -0.01 -0.12 <0.0001   0.00 -0.04 <0.0001 
2-hour Post Load Plasma Glucose 0.02 0.15 <0.0001   0.03 0.18 <0.0001   0.01 0.17 <0.0001 
Fasting Plasma Glucose 0.04 0.16 <0.0001   0.08 0.19 <0.0001   0.02 0.14 <0.0001 
Ln(Triglycerides) 0.01 0.14 <0.0001   0.00 0.05 0.015   0.01 0.08 <0.0001 
Systolic Blood Pressure 0.09 0.05 0.001   0.28 0.13 <0.0001   0.16 0.11 <0.0001 
HOMA-S -1.05 -0.16 <0.0001   -1.13 -0.25 <0.0001   -2.42 -0.42 <0.0001 
Ln(Triglyceride) 
(mmol/L) 
HDL Cholesterol -0.06 -0.10 <0.0001   -0.10 -0.15 <0.0001   -0.01 -0.02 0.049 
2-hour Post Load Plasma Glucose 0.21 0.12 <0.0001   0.42 0.14 <0.0001   0.06 0.10 <0.0001 
Fasting Plasma Glucose 0.53 0.13 <0.0001   0.94 0.14 <0.0001   0.15 0.08 <0.0001 
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Waist Circumference 0.12 0.01 0.537   -0.08 0.00 0.758   0.25 0.02 0.016 
Systolic Blood Pressure 0.74 0.03 0.084   2.18 0.06 0.001   0.78 0.04 <0.0001 
HOMA-S -6.95 -0.06 0.001   -9.89 -0.13 <0.0001   -15.61 -0.21 <0.0001 
Systolic Blood 
Pressure (mmHg) 
HDL Cholesterol 0.00 -0.01 0.652   0.00 -0.06 0.013   0.00 -0.03 <0.0001 
2-hour Post Load Plasma Glucose 0.01 0.10 <0.0001   0.00 0.03 0.183   0.00 0.04 0.002 
Fasting Plasma Glucose 0.01 0.08 <0.0001   0.02 0.06 0.009   0.01 0.07 <0.0001 
Waist Circumference 0.00 0.01 0.637   -0.01 -0.01 0.535   0.01 0.01 0.448 
Ln(Triglycerides) 0.00 0.02 0.122   0.00 0.01 0.773   0.00 0.02 0.134 
HOMA-S -0.07 -0.02 0.400   -0.18 -0.06 0.006   -0.63 -0.14 <0.0001 
Homa %S 
HDL Cholesterol 0.00 0.14 <0.0001   0.00 0.12 <0.0001   0.00 0.03 0.001 
2-hour Post Load Plasma Glucose -0.01 -0.08 <0.0001   -0.02 -0.14 <0.0001   0.00 -0.04 0.001 
Fasting Plasma Glucose -0.02 -0.12 <0.0001   -0.04 -0.16 <0.0001   0.00 -0.08 <0.0001 
Waist Circumference -0.01 -0.02 0.148   -0.01 -0.02 0.245   -0.01 -0.03 <0.0001 
Ln(Triglycerides) 0.00 -0.10 <0.0001   0.00 -0.02 0.264   0.00 -0.04 0.001 
Systolic Blood Pressure -0.06 -0.06 <0.0001   -0.11 -0.09 <0.0001   -0.02 -0.05 <0.0001 
 
1Each linear regression model includes a single baseline MetS component plus age, sex, the dependent variable at 
baseline (not shown – included in order to model change) and (in Mauritius) ethnic group as covariates. 
2Units for outcome variables are identical to those of the corresponding variable from baseline in column 1. 
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Table 3. Multiple regression analysis of baseline MetS components and change in each other component between baseline and 
follow-up. 
  
Mauritius 1987-1992   Mauritius 1987-1998   AusDiab 2000-2005 
Baseline predictor variable1 Outcome variable at followup2 Coef. 
Std 
Beta P   Coef. 
Std 
Beta P   Coef. 
Std 
Beta P 
HDL Cholesterol (mmol/L) 
2-hour Post Load Plasma Glucose 0.036 0.01 0.494   0.068 0.01 0.573   -0.036 -0.02 0.132 
Fasting Plasma Glucose 0.022 0.00 0.866   0.099 0.01 0.713   0.008 0.00 0.913 
Waist Circumference -0.133 0.00 0.681   0.515 0.02 0.263   -0.641 -0.02 0.047 
Ln(Triglycerides) -0.096 -0.06 <0.0001   -0.096 -0.07 0.001   -0.094 -0.07 <0.0001 
Systolic Blood Pressure -0.633 -0.01 0.416   -0.190 0.00 0.868   0.607 0.01 0.406 
HOMA-S 13.194 0.07 <0.0001   9.789 0.08 <0.0001   25.036 0.13 <0.0001 
Fasting Plasma Glucose (mmol/L) 
HDL Cholesterol 0.007 0.01 0.545   0.025 0.04 0.129   0.001 0.00 0.884 
2-hour Post Load Plasma Glucose 0.585 0.13 <0.0001   0.828 0.11 <0.0001   0.319 0.09 <0.0001 
Waist Circumference -0.126 -0.01 0.561   -0.002 0.00 0.995   -0.542 -0.02 0.020 
Ln(Triglycerides) 0.050 0.05 0.001   0.032 0.04 0.108   0.018 0.02 0.163 
Systolic Blood Pressure 0.658 0.02 0.207   0.328 0.01 0.670   0.706 0.02 0.180 
HOMA-S 3.226 0.03 0.175   5.523 0.07 0.003   -7.591 -0.05 0.001 
2-hour Post Load Plasma Glucose 
(mmol/L) 
HDL Cholesterol 0.003 0.01 0.478   -0.001 0.00 0.876   -0.002 -0.01 0.524 
Fasting Plasma Glucose 0.075 0.12 <0.0001   0.176 0.16 <0.0001   0.025 0.07 <0.0001 
Waist Circumference -0.165 -0.03 0.022   -0.322 -0.05 0.001   0.015 0.00 0.825 
Ln(Triglycerides) 0.002 0.01 0.665   0.007 0.02 0.248   -0.004 -0.01 0.295 
Systolic Blood Pressure 0.039 0.00 0.821   0.095 0.01 0.700   0.136 0.01 0.374 
HOMA-S -0.821 -0.02 0.300   0.150 0.01 0.804   -2.116 -0.04 0.002 
Waist Circumference (cm) 
HDL Cholesterol -0.002 -0.06 0.002   -0.002 -0.05 0.055   0.000 -0.02 0.170 
2-hour Post Load Plasma Glucose 0.011 0.11 <0.0001   0.021 0.12 <0.0001   0.005 0.12 <0.0001 
Fasting Plasma Glucose 0.029 0.12 <0.0001   0.057 0.13 <0.0001   0.010 0.08 <0.0001 
Ln(Triglycerides) 0.006 0.11 <0.0001   0.002 0.04 0.085   0.001 0.03 0.021 
Systolic Blood Pressure 0.047 0.03 0.142   0.232 0.11 <0.0001   0.134 0.09 <0.0001 
HOMA-S -0.897 -0.14 <0.0001   -0.972 -0.21 <0.0001   -1.828 -0.32 <0.0001 
Ln(Triglyceride) (mmol/L) HDL Cholesterol -0.038 -0.06 0.001   -0.076 -0.12 <0.0001   -0.007 -0.01 0.340 
2-hour Post Load Plasma Glucose 0.119 0.07 <0.0001   0.262 0.09 <0.0001   0.042 0.04 0.008 
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Fasting Plasma Glucose 0.352 0.08 <0.0001   0.588 0.09 <0.0001   0.163 0.05 0.002 
Waist Circumference 0.064 0.00 0.746   -0.048 0.00 0.864   0.239 0.01 0.268 
Systolic Blood Pressure -0.011 0.00 0.982   0.707 0.02 0.312   1.011 0.03 0.038 
HOMA-S -3.753 -0.03 0.084   -5.453 -0.07 0.001   -13.086 -0.10 <0.0001 
Systolic Blood Pressure (mmHg) 
HDL Cholesterol 0.001 0.04 0.041   0.000 -0.02 0.389   -0.001 -0.02 0.013 
2-hour Post Load Plasma Glucose 0.003 0.05 0.008   -0.002 -0.02 0.452   0.000 0.00 0.908 
Fasting Plasma Glucose 0.003 0.02 0.297   -0.001 0.00 0.890   0.002 0.02 0.171 
Waist Circumference 0.004 0.01 0.605   -0.002 0.00 0.867   0.005 0.01 0.447 
Ln(Triglycerides) 0.000 -0.01 0.700   0.000 0.00 0.996   0.001 0.02 0.190 
HOMA-S -0.017 0.00 0.828   -0.109 -0.04 0.095   -0.263 -0.06 <0.0001 
Homa %S 
HDL Cholesterol 0.002 0.10 <0.0001   0.002 0.07 0.009   0.000 0.02 0.056 
2-hour Post Load Plasma Glucose 0.002 0.03 0.194   -0.003 -0.02 0.393   0.000 0.01 0.330 
Fasting Plasma Glucose 0.000 0.00 0.909   -0.012 -0.05 0.082   -0.001 -0.02 0.129 
Waist Circumference -0.015 -0.02 0.079   -0.023 -0.03 0.052   -0.011 -0.03 <0.0001 
Ln(Triglycerides) -0.001 -0.02 0.348   0.001 0.03 0.207   0.000 0.00 0.814 
Systolic Blood Pressure -0.039 -0.04 0.054   -0.024 -0.02 0.415   -0.003 -0.01 0.604 
 
.1Each linear regression model includes all six baseline MetS components plus age, sex, the dependent variable at baseline 
(not shown – included in order to model change) and (in Mauritius) ethnic group as covariates. 
2Units for outcome variables are identical to those of the corresponding variable from baseline in column 1 
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Figure 1. Relationships between MetS components at baseline and change in another 
individual component between baseline and follow-up. Linear regression adjusted for 
all variables shown at baseline in addition to age, sex and (in Mau ritius) ethnic group. 
Results for AusDiab 2000-2005, Mauritius 1987-1992 and Mauritius 1987-1998. Data 
from Table 4. 
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